MEDICINA
Departamento
Instituto de Biomedicina de Sevilla
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biomedicina de Sevilla (22)
2024
-
Long or complicated mpox in patients with uncontrolled HIV infection
Journal of Medical Virology, Vol. 96, Núm. 3
2022
-
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
Journal of Infection, Vol. 85, Núm. 3, pp. 322-326
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
-
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study
The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792
-
Mesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial
Stem Cells Translational Medicine, Vol. 10, Núm. 4, pp. 534-541
-
Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency
Archivos de Bronconeumologia, Vol. 57, Núm. 1, pp. 42-50
-
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252
2020
-
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
-
Telephone Support for Copd Patients During COVID-19
Open Respiratory Archives, Vol. 2, Núm. 3, pp. 179-185
-
The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency
COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 17, Núm. 4, pp. 346-354
2019
-
Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH
Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676
-
Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy
Annals of Hematology, Vol. 98, Núm. 8, pp. 1953-1959
2018
-
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349
-
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))
Gastroenterologia y Hepatologia
-
Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance—Supercontrollers
Frontiers in Immunology, Vol. 9
-
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C
Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948
2017
-
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311
2014
-
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting
HIV Medicine, Vol. 15, Núm. 7, pp. 417-424